CD40 DNA Aptamer Adjuvants for Low-Immunogenicity Vaccines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CD40 agonists, such as anti-CD40 monoclonal antibodies, are costly and highly immunogenic, making them impractical for use as vaccine adjuvants in industries with tight profit margins, and there is a need for alternative biomolecules with low-immunogenicity for enhancing immune responses.
Innovation Solution
Development of immunostimulatory nucleic acids, specifically DNA aptamers with high specificity and affinity for CD40, which are produced through SELEX and used to create immunostimulatory complexes with antigens to enhance immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD40 monoclonal antibodies are used as CD40 agonists, then immune response stimulation is achieved, but production cost increases and immunogenicity worsens
Solution Approach 1:
The patent uses DNA aptamers as simplified copies that mimic the function of anti-CD40 monoclonal antibodies. These aptamers bind to CD40 and stimulate immune responses without the high immunogenicity and production costs associated with full monoclonal antibodies, achieving the desired immune stimulation through a less complex molecular structure
Solution Approach 2:
The patent employs DNA aptamers as cost-effective alternatives to expensive monoclonal antibodies. DNA aptamers can be synthesized more cheaply and are less immunogenic, making them suitable for applications where cost and immunogenicity are concerns while still achieving the necessary immune response stimulation
2Reliability
If anti-CD40 monoclonal antibodies are used as vaccine adjuvants, then immune response enhancement is achieved, but production cost increases
Solution Approach 1:
The patent replaces expensive monoclonal antibody adjuvants with DNA aptamer copies that replicate the essential CD40-stimulating function. This substitution dramatically reduces production costs while maintaining the ability to enhance immune responses in vaccine applications
Solution Approach 2:
The patent uses synthetically produced DNA aptamers as inexpensive substitutes for costly monoclonal antibody adjuvants. The DNA-based approach enables lower-cost manufacturing and distribution of vaccine adjuvants while preserving the desired immunoenhancement effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DNA aptamers effectively stimulate immune responses, demonstrating elevated antibody titers and robust immune activation, offering a cost-effective and less immunogenic alternative to traditional CD40 agonists.
Implementation Method 1
DNA aptamers with high specificity and affinity for the CD40 protein, which are synthesized to mimic the CD40-CD40L interaction
Data Source
AI summary
The present invention provides immunostimulatory nucleic acids that have an affinity to a specific target protein. The present invention also provides templates and methods for making and using the immunostimulatory nucleic acids. Further, methods for linking the immunostimulatory nucleic acids to antigens and using the resulting complexes to enhance an immune response are provided.